In 2009, the Iressa Pan-Asian Study (IPASS) established a new standard of care for the first-line treatment of patients with NSCLC who harbor activating epidermal growth factor receptor (EGFR) mutations, which are primarily observed in subjects who are Asian, women, former light or non-smokers, and adenocarcinoma patients [2,3]. The gene discussed is EGFR; the disease is adenocarcinoma.